
Secondary Logo

Q

Journal Logo



ARTICLE: FUNCTIONAL GI DISORDERS

Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial

Q

Nee, Judy MD¹; Ballou, Sarah PhD¹; Kelley, John M. PhD^{2,3}; Kaptchuk, Ted J.²; Hirsch, William BS¹; Katon, Jesse BS¹; Cheng, Vivian MS, MPH¹; Rangan, Vikram MD¹; Lembo, Anthony MD¹; Iturrino, Johanna MD¹

Author Information

¹Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;

²Program in Placebo Studies, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;

³Department of Psychology, Endicott College, Beverly, Massachusetts, USA.

Correspondence: Judy Nee, MD. E-mail: jnee@bidmc.harvard.edu.

SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/AJG/C124, https://links.lww.com/AJG/C125, https://links.lww.com/AJG/C126, and https://links.lww.com/AJG/C127.

The American Journal of Gastroenterology: November 2021 - Volume 116 - Issue 11 - p 2279-2285

doi: 10.14309/ajg.0000000000001395

- Buv
- SDC

Metrics

Abstract

INTRODUCTION:

Peppermint oil is often used to treat irritable bowel syndrome (IBS); however, the overall quality of previous studies is low, and findings have been heterogeneous. This study aimed to compare the effects of peppermint oil vs placebo in relieving IBS symptoms.

METHODS:

In a 6-week, randomized, double-blind, placebo-controlled trial at a single academic center in the United States, individuals diagnosed with IBS (Rome IV criteria), with moderate to severe symptoms based on the IBS Severity Scoring System (IBS-SSS score \geq 175), were randomized to enteric-coated peppermint oil 180 mg 3 times daily vs placebo in a 1:2 ratio. The primary outcome was mean change in IBS-SSS scores from baseline to 6-week endpoint.

RESULTS:

A modified intent-to-treat analysis revealed that there were substantial mean improvements from baseline to 6-week endpoint in the main outcome measure (IBS-SSS) for both peppermint oil (90.8, SD = 75.3) and placebo (100.3, SD = 99.6). Although the peppermint oil group reported numerically lower improvement than the placebo group, the effect size was small (d = -0.11), and the difference between the groups was not statistically significant (P = 0.97). Similarly, both groups reported substantial improvements on the secondary endpoints; but again, there were no statistically significant differences between the groups on any of the secondary measures. Sensitivity analyses using multiple imputation to replace missing data produced similar results and revealed no significant differences between peppermint oil and placebo on any outcome measure.

DISCUSSION:

Peppermint oil and placebo both showed clinically meaningful improvement in IBS symptoms. However, there were no significant differences between the groups. Further large, rigorous trials are needed to evaluate the role of peppermint oil for the treatment of IBS.

© 2021 by The American College of Gastroenterology ^Back to Top



Never Miss an Issue

Get new journal Tables of Contents sent right to your email inbox Get New Issue Alerts

Browse Journal Content

- Most Popular
- For Authors
- About the Journal
- · Past Issues
- Current Issue
- Subscribe
- Get eTOC Alerts

My Account

- Profile
- Subscriptions
- Favorites
- Saved Searches

For Journal Authors

- · Submit an article
- How to publish with us

Customer Service

- Activate your journal subscription
- Activate Journal Subscription
- Browse the help center
- Help
- Contact us at:
 - EMAIL: customerservice@lww.com
 - TEL: 800-638-3030 (within the USA) 301-223-2300 (outside of the USA)
- Privacy Policy (Updated June 1, 2020)
- · Legal Disclaimer
- · Terms of Use
- Open Access Policy
- Copyright © 2021
- Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved.